Introduction {#S0001}
============

Gastric cancer (GC) is the fifth most common malignancy worldwide and the third leading cause of cancer-related mortality.[@CIT0001] The mortality rate for GC has continued to increase in the past decade and the high mortality rate reflects the prevalence of advanced stage at presentation, especially in China.[@CIT0002] Currently, for patients with pT1-stage GC, radical surgery (including endoscopic mucosal and submucosal dissection) can be performed to peruse curative outcome, and the postoperative 5-year survival rate can reach 85--95%. However, in China, patients with advanced gastric cancer (AGC) account for nearly 80% of the total number, and the postoperative 5-year survival rate remains only 30--50%. This situation indicates that for most patients with AGC, even if an expanded scope of surgical resection and lymph node dissection were performed, surgery alone or surgery plus chemotherapy cannot achieve the goal of radical cure. Therefore, the concept of preoperative chemotherapy, also known as neoadjuvant chemotherapy (NACT), was proposed to improve the radical resection rate and control preoperative micrometastasis.

In the early 1990s,[@CIT0003] the literature reported the application of neoadjuvant chemotherapy in patients with resectable GC, mostly regimens based on 5-fluorouracil, combined with adriamycin (ADM), mitomycin (MMC), and cisplatin (DDP). In these studies, the median survival time of neoadjuvant chemotherapy was 15--40 months, which was significantly better than that of patients who received surgery alone[@CIT0004]--[@CIT0008] In 2006, the MAGIC study (a Phase III, randomized, controlled study) conducted a trial of patients who received three cycles of epirubicin, cisplatin, and fluorouracil (ECF) as chemotherapy before and after surgery and the control group who received surgery alone,[@CIT0009] and found that the overall survival (OS) rate of the perioperative chemotherapy group was significantly better than that of the surgery-alone group (36% vs 23%, HR, 0.75; 95% CI, 0.60--0.93; *P*=0.0009). In another multicenter randomized controlled trial from France (FNCLCC ACCORD 07-FFCD 9703), preoperative application of 5-FU and cisplatin versus surgery alone resulted in OS rates of 38% and 24%, respectively (*P*=0.02) and disease-free survival rates of 34% and 19%, respectively (*P*=0.003).[@CIT0010] Furthermore, the results of the Phase II/III multicenter randomized controlled trial (FLOT4-AIO) showed that the FLOT regimen was significantly superior to the ECF/ECX regimen of the MAGIC trial in terms of OS (HR, 0.0.77; 95% CI, 0.63--0.94; *P*=0.012).[@CIT0011] The positive impact of preoperative chemotherapy on survival in patients with resectable AGC has been confirmed by many meta-analyses,[@CIT0012],[@CIT0013] although there is no consensus as to the best regimen.

Due to the lack of adequate treatment experience and because the efficacy of NACT has not been clearly verified for Chinese patients, most practitioners still prefer initial surgery once the diagnosis was made. In addition, no study to date has directly compared the efficacy of FLOT as NACT regimen with that of initial surgery followed by adjuvant chemotherapy. Therefore, we designed this study to investigate the relative benefit of FLOT regimen as NACT compared with initial surgery for Chinese patients with resectable locally advanced gastric cancer (LAGC) and investigated the subgroup of patients who would be having better benefits.

Methods {#S0002}
=======

Patients enrollment {#S0002-S2001}
-------------------

From January 2013 to December 2017, clinical data of 341 patients with LAGC who underwent radical gastrectomy were collected at the Department of General Surgery, Lanzhou University Second Hospital.

The eligibility criteria were as follows: 1) preoperative cT3--4; 2) histologically proven adenocarcinoma; 3) underwent D2 or extended D2 lymphadenectomy; 4) complete clinical records; 5) no distant metastasis such as liver, lung or bone; 6) \<75 years old; and (7) Eastern Cooperative Oncology Group (ECOG) score 0--2 points.

The exclusion criteria were as follows: 1) previous history of other cancers; 2) gastric stump cancer; and 3) received preoperative radiotherapy. Ultimately, a total of 316 patients who met the criteria were included in this study, representing 92.7% of the total number of patients with LAGC during the same period. The requirement to obtain written informed consent from patients was waived because of the retrospective nature of this study. The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Lanzhou University Second Hospital.

Treatment {#S0002-S2002}
---------

Patients in the NACT group received at least 1 week of preoperative chemotherapy with the FLOT regimen consisting of docetaxel (60 mg/m^2^), oxaliplatin (85 mg/m^2^), leucovorin (200 mg/m^2^), and 5-fluorouracil (2,600 mg/m^2^ as a 24 hr infusion), all given on day 1. This procedure was performed every 2 weeks and surgery was followed 3 weeks after chemotherapy was completed. Patients underwent imaging evaluation (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) after receiving FLOT neoadjuvant. If the tumor resolved, the patients finished three cycles of preoperative chemotherapy. If the imaging evaluation revealed the chemotherapy ineffective or the tumor progressed, surgery was performed directly. Patients in the two groups all received at least one cycle of adjuvant chemotherapy after surgery, and we preferred to use FLOT. If the FLOT regimen was not tolerated due to toxic reaction, then it was replaced by XELOX (oxaliplatin 130 mg/m^2^ on day 1; xeloda 1,000 mg/m^2^ twice a day, on day 1--14), SOX (oxaliplatin 130 mg/m^2^ on day 1; tegafur 40 mg/m^2^ twice a day, on day 1--14), or FOLFOX6 (oxaliplatin 85 mg/m^2^, leucovorin 200 mg/m^2^ on, and 5-fluorouracil 2,600 mg/m^2^) regimens. All patients in our study underwent total, subtotal, or distal gastrectomy based on the primary tumor size and location. The strategy for lymph node dissection was taken by standard D2 or extended D2 lymphadenectomy.

Data collection {#S0002-S2003}
---------------

After reviewing medical records, we obtained data on age, sex, time of diagnosis, tumor location, preoperative ECOG score, clinical TNM stage, Lauren classification, style of operation, regimen of adjuvant chemotherapy, depth of tumor invasion, and number of positive lymph nodes in all patients. Depth of tumor invasion was utilized to stage tumors according to the 7th edition AJCC guidelines.[@CIT0014] The primary endpoint in this study was OS, which was calculated from the time of the any form of treatment since diagnosis to the date of death (for any reason) or the most recent follow-up. The secondary endpoint was response, which was evaluated by CT scan in each cycle according to RECIST criterion v 1.1, and compared with the baseline CT scan performed before treatment.

Statistical analysis {#S0002-S2004}
--------------------

Associations between treatment modality and patients' demographic, clinical, and facility characteristics were assessed using Pearson χ^2^ or Fisher's exact test for categorical data and independent-sample t test for continuous variables, respectively. To reduce bias from nonrandom treatment assignments, two models of the association between OS and treatment modality based on propensity score analysis were constructed: propensity score-matched (PSM) and weighting by inverse probability of treatment (IPTW). The propensity score analysis of receipt of NACT was used to take into account all baseline covariates into a nonparsimonious manner and was constructed using a multivariable logistic regression model, which contained age, gender, tumor location, clinical TNM stage, Lauren classification, and year of diagnosis. The Hosmer and Lemeshow goodness-of-fit statistics and the area under the receiver operating characteristic curve (AUC) were calculated to evaluate the adequacy of the model.

For the matched-patient analysis, patients treated with NACT were matched 1:1 to patients who received initial surgery on propensity score with a caliper of 0.05. We also assessed the heterogeneity of treatment effects with tests of interaction and subgroup analysis that explored the effect of age, gender, clinical TNM stage, and tumor location. Moreover, based on the propensity score, an IPTW analysis was conducted. Patients who received first-line FLOT were weighted by 1/propensity score, whereas patients who underwent first-line surgery were weighted by 1/(1− propensity score).

In both models, Kaplan--Meier curves with the log-rank tests were used to calculate the overall cumulative probability. Univariate and multivariate Cox models were performed to compare the groups in the PSM analysis. A *P*-value \<0.05 was considered statistically significant. Statistical analyses were conducted using Statistical Product for Social Sciences (SPSS) software (version 23.0; Inc, Chicago, IL, USA) and Empower-Stats (<http://www.empowerststs.com>, X&Y Solutions, Inc, Boston, MA, USA).

Results {#S0003}
=======

Patients' characteristics {#S0003-S2001}
-------------------------

From 2013 to 2017, a total of 316 LAGC patients were included in this study, of whom 47 patients received preoperative FLOT regimen chemotherapy and 269 patients received initial surgery after diagnosis. The baseline data of the patients are shown in [Table 1](#T0001){ref-type="table"}. As shown in [Table 1](#T0001){ref-type="table"}, there was a significant difference between the two groups in the clinical TNM stage and the time of diagnosis. The propensity score obtained by multivariate logistic regression analysis showed an AUC of 0.75 and a *P*-value of the Hosmer--Lemeshow test of 0.414, which suggested a reasonable data model.Table 1Demographic and clinical characteristics before and after PSM analysisVariablesBefore PSM (n=316)*P-*valueAfter PSM (n=82)*P-*valueSurgery-first\
n=269FLOT-first\
n=47Surgery-first\
n=41FLOT-first\
n=41n (%)n (%)n (%)n (%)Age (years)0.91 \<60152 (56.5)27 (57.4)24 (58.5)23 (56.1) ≥60117 (43.5)20 (42.6)17 (41.5)18 (43.9)Gender0.281 Male196 (72.9)38 (80.9)32 (78)33 (80.5) Female73 (27.1)9 (19.1)9 (22)8 (19.5)Lauren classification0.80.36 Intestinal118 (43.9)20 (42.6)18 (43.9)15 (36.6) Diffuse85 (31.6)17 (36.2)10 (24.4)16 (39) Mixed66 (24.5)10 (21.3)13 (31.7)10 (24.4)Tumor location0.340.87 Upper third65 (24.4)13 (27.7)12 (29.3)10 (24.4) Middle third116 (43.6)24 (51.1)19 (46.3)21 (51.2) Lower third85 (32.0)10 (21.3)10 (24.4)10 (24.4)Clinical TNM stage0.011 II119 (44.2)11 (23.4)11 (26.8)11 (26.8) III150 (55.8)36 (76.6)30 (73.2)30 (73.2)Diagnose time0.0011 2013\~2014100 (37.2)7 (14.9)7 (17.1)7 (17.1) 2015\~2016132 (49.1)17 (36.2)17 (41.5)17 (41.5) 201737 (13.8)23 (48.9)17 (41.5)17 (41.5)[^1]

Survival analysis {#S0003-S2002}
-----------------

The median follow-up time for the entire study was 41 months (12--67 months). In the unmatched study, the median survival time for patients in the initial FLOT group and that in the initial surgery group was 44 months and 23 months (*P*=0.01), respectively. The 3-year survival rates in the initial FLOT group and that in the initial surgery group were 60.1% and 36.5%, respectively; the 5-year survival rates were 43.8% and 26.8%, respectively ([Figure 1A](#F0001){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}). The results of the multivariate analyses showed that treatment approach and clinical TNM stage were independent factors affecting patients' survival. In addition, the adjusted HR of FLOT-first compared with surgery-first for OS was 0.417 (95% CI, 0.23--0.755, *P*=0.004) (Table S1). In the head-to head PSM analysis, 41 patients treated with FLOT-first and 41 patients treated with surgery-first were successfully matched, and the age, sex, tumor location, Lauren classification, clinical TNM stage, and time of diagnose were balanced between the two groups ([Table 1](#T0001){ref-type="table"}). The results of the multivariate analysis indicated that initial FLOT was associated with a significant OS benefit compared with initial surgery (HR, 0.416; 95% CI, 0.218--0.794; *P*=0.008) ([Table 3](#T0003){ref-type="table"}). The median survival time for patients in the FLOT-first group and that in the surgery-first group was 44 months and 15 months (*P*=0.008), respectively. The 3-year survival rate in the FLOT-first group and surgery-first group was 58.7% and 30.9%, respectively ([Figure 1B](#F0001){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}). The IPTW analysis showed a similar result; The 3-year survival rate in the FLOT-first group and the surgery-first group was 68.6% and 35.4% (*P*\<0.001), respectively ([Figure 1C](#F0001){ref-type="fig"}, [Table 2](#T0002){ref-type="table"}). In the exploratory subgroup analysis of the matched cohort, there were no significantly different effects of FLOT on OS across all subgroups examined ([Figure 2](#F0002){ref-type="fig"}). However, in stage II subgroup, patients who received FLOT-first treatment did not show a beneficial survival (HR, 0.868; 95% CI, 0.215--3.504).Table 2Overall survival for FLOT-first versus surgery-first in patients with locally advanced gastric cancerYearUnmatched (%)PSM (%)IPTW (%)FLOTSurgeryFLOTSurgeryFLOTSurgery185.870.884.466.891.570.5269.048.167.537.174.646.7360.136.558.730.968.635.4443.829.842.823.250.628.9543.826.8------26.0[^2] Table 3Univariate and multivariate analysis of survival in PSM analysis (n=82)VariablesUnivariate analysis*P-*valueMultivariate analysis*P-*valueHR95% CIHR95% CITreatment0.0110.008 FLOT-first0.4340.228\~0.8260.4160.218\~0.794 Surgery-first11Age (years)0.103 \<601 ≥601.6990.899\~3.209Gender0.161 Male1 Female1.6250.824\~3.205Lauren classification0.648 Intestinal1 Diffuse1.3860.651\~2.953 Mixed1.3320.620\~2.859Tumor location0.674 Upper third1 Middle third1.1470.485\~2.709 Lower third1.4810.578\~3.79Clinical TNM stage0.0440.032 II11 III2.2411.021--4.9162.3781.076\~5.265Diagnose time0.305 2013\~20141 2015\~20160.4760.175\~1.29 20170.6410.303\~1.356Postoperative chemotherapy0.122 FLOT1 FOLFOX61.1940.36\~3.964 XELOX2.7690.369\~20.76 SOX2.3241.13\~4.778Style of operation0.095 Total gastrectomy1 Subtotal gastrectomy1.2920.66\~2.53 Distal gastrectomy0.4350.158\~1.201[^3] Figure 1Overall survival in **(A)** the unmatched, **(B)** the propensity score-matched analysis, **(C)** the inverse probability of treatment weight-adjusted analysis according to the different initial treatments in patients with clinical T3--4 locally advanced gastric cancer.**Abbreviation:** FLOT, docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil.Figure 2Subgroup analysis in the propensity score-matched analysis.**Abbreviation:** FLOT, docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil.

Response and toxicity analysis {#S0003-S2003}
------------------------------

In this study, only 1 (2.1%) patient achieved CR, 15 (42.6%) patients achieved PR, 17 (44.7%) patients were in SD, and 3 (6.4%) patients were in progressive disease (PD) according to CT contrast before and after chemotherapy. Two patients' data were lost. After surgery, 1 (2.1%) patient was not found to have cancer tissue (PCR), and the R0 resection rate was 91% in the FLOT-first cohort ([Table 4](#T0004){ref-type="table"}). In the FLOT-first cohort, the results of multivariate analysis showed that the response to chemotherapy (HR, 8.21; 95% CI, 1.66--40.56, *P*=0.005) and gender (HR, 6.322; 95% CI, 1.75--22.91; *P*=0.01) were independent factors associated with survival (Table S2). Throughout the course of chemotherapy, the main grade 3--4 toxicities were mainly leukopenia (36%), dizziness (9%), nausea (25%), and vomiting (3%). No patient dropped out due to severe toxic reactions. In addition, G-CSF was administered in 23 patients and no treatment-related death occurred.Table 4Tumor response according to RECIST 1.1 criteriaTumor responseNumber of patients%95% CICR12.1PR2042.6CR+PR2144.730.5--58.9SD2144.7PD36.4NE24.2[^4]

Postoperative pathology results {#S0003-S2004}
-------------------------------

The extent of resection, surgical complications, pT stage of tumor invasion, and pN stage of lymph node according to the 7th edition AJCC guidelines are summarized in [Table 5](#T0005){ref-type="table"}.[@CIT0014] We can conclude that in the unmatched study, the R0 resection rate was 88.4% in the FLOT group and 86.4% in the surgery group. In the PSM analysis, the R0 resection rate was 89.2% in the FLOT group and 84.6% in the surgery group (all *P*\>0.05). After surgery, there was significant difference only in the pN stage between the two groups after PSM (*P*=0.006), and percentage of patients without lymph node metastasis was slightly high in the FLOT-first cohort.Table 5Postoperative pathology reportVariablesBefore PSM*P*-valueAfter PSM*P*-valueFLOT-first\
n=47Surgery-first\
N=269FLOT-first\
n=41Surgery-first\
N=41n (%)n (%)n (%)n (%)R0 resection0.7290.737 Yes38 (88.4)223 (86.4)33 (89.2)33 (84.6) No5 (11.6)35 (13.6)4 (10.8)6 (15.4) Missing41142pT0.0940.491 T01 (2.3)--1 (2.7)0 T21 (2.3)7 (2.7)1 (2.7)2 (5.1) T313 (30.2)68 (26.4)12 (32.4)8 (20.5) T428 (65.1)183 (70.9)23 (62.2)29 (74.4) Missing41142pN0.1220.006 N017 (39.5)66 (25.6)15 (40.5)3 (7.7) N110 (23.3)48 (18.6)7 (18.9)7 (18.9) N27 (16.3)50 (19.4)7 (18.9)12 (30.8) N39 (20.9)94 (36.4)8 (21.6)17 (43.6) Missing41142Major surgical complications^a^0.8310.519 Yes8 (17)41 (16)4 (9.8)7 (17.1) No39 (83)215 (84)37 (90.2)34 (82.9) Missing-13\--[^5]

Discussion {#S0004}
==========

The positive impact of neoadjuvant chemotherapy on survival in patients with locally advanced gastric adenocarcinoma has become clearer over time, although there is no consensus as to the best approach. The best chemotherapy regimen for neoadjuvant therapy is not established, and practice is variable. Although the FLOT regimen demonstrated higher 5-year survival and disease-free survival rates in the treatment of GC and gastroesophageal junction cancer than the previous regimen,[@CIT0011] whether this regimen can achieve similar results in GC patients in China has not been reported.

Our head-to-head study based on the propensity score, for the first time, directly compared the survival benefit of preoperative FLOT chemotherapy with initial surgery followed by adjuvant chemotherapy. We found that patients who received neoadjuvant chemotherapy with the FLOT regimen had a lower mortality rate and a median survival time of approximately 10 more months compared with patients who underwent initial surgery. This benefit profile is consistent with that obtained in the IPTW study, and the consistency of the results from these two analyses can further support our conclusions.

For patients with potentially resectable AGC, randomized trials and meta-analyses indicate a significant survival benefit over surgery alone for the number of approaches, including neoadjuvant chemotherapy. At least four trials have directly compared surgery alone with neoadjuvant or perioperative chemotherapy, three of which demonstrated a survival benefit for this approach. In the Phase III MAGIC trial,[@CIT0009] the HR of the ECF regimen compared with surgery for OS was 0.75 (95% CI, 0.60--0.93). In the large multicenter randomized controlled trial 07-FFCD 9703 in France,[@CIT0010] the HR was 0.69 (95% CI, 0.50--0.95) in the DCF regimen compared with the surgery alone. Fiteni et al[@CIT0015] conducted a large retrospective study based on the propensity score. In Fiteni's study, the DCF regimen was compared with the surgery group, and the 5-year survival rate was 0.293 (95% CI, 0.135--0.636) in the treatment of gastroesophageal junction cancer. In these three studies, R0 resection rates were 69%, 84%, and 90.32%. These results illustrate the potential superiority of docetaxel in the neoadjuvant chemotherapy regimen. In our study, the adjusted HR was 0.417 (95% CI, 0.23--0.755) for the FLOT-first compared with surgery-first, and the 3-year survival rate was 60.1%. The 3-year survival rate was similar to the 57% result in the stage III FLOT-AIO4 trial and 60% in the Fiteni study and is superior to the 45% in the MAGIC trial and 50% in FFCD trial.[@CIT0009],[@CIT0010],[@CIT0016] Although the biological behavior of gastroesophageal junction cancer and distal GC included in these studies are different, the results may indicate the potential advantages of FLOT as a neoadjuvant chemotherapy regimen. In addition, the R0 resection rate in our study was 88.4%, which is similar to the result of 86% reported in a Phase II clinical study (Neo-FLOT) in Germany, where the patients included were (consistent with our study) all in cT3--4 stage.[@CIT0017] Furthermore, there was a significant difference in postoperative lymph node N stage between the two groups in the PSM analysis, and the number of patients without lymph node metastasis was slightly high in the FLOT-first cohort, which may mean that the number of lymph node metastases can be reduced by the FLOT regimen to achieve the goal of downstage treatment. A meta-analysis conducted by Coccolini F also reached a similar conclusion.[@CIT0013] In addition, in the further subgroup analysis, we found that for stage II patients, preoperative FLOT chemotherapy did not show a better benefit (HR, 0.868, 95% CI, 0.215--3.504). This indicated that the FLOT regimen might not be effective in patients without lymph node metastasis, because only cT3--4 patients were included in our study, and those with stage II had no lymph node metastasis.

Previous findings have confirmed that response to chemotherapy is closely related to the prognosis of patients with GC and gastroesophageal junction cancer,[@CIT0018],[@CIT0019] and this conclusion is also consistent with the results of our research. In the Neo-FLOT study,[@CIT0017] PCR in the FLOT regimen reached 20% and RR reached 40%. In the FLOT4 trial, PCR reached 15% and 16% in gastric and gastroesophageal junction cancers, respectively.[@CIT0011] In addition, PCR was 5% in the study by Simon, and the response rate was even higher at 66%.[@CIT0020] Although only 1 patient in our study achieved PCR (7%), which is lower than the above study, the overall response rate reached 44.7% and is better than the overall response rate of 37% in the V325 study,[@CIT0021] which also included a docetaxel-containing DCF regimen. Although limited by the fact that this comparison was made between different trials, we cannot directly conclude that the FLOT regimen is superior to other docetaxel-containing chemotherapy regimens; however, this result still demonstrates the potential superiority of FLOT over DCF and other docetaxel-containing chemotherapy regimens in terms of chemotherapy effectiveness.

There is no doubt that chemotherapy regimens including docetaxel increase the risk of hematologic toxicities and nonhematologic side effects. In the FLOT4 trial,[@CIT0011] chemotherapy-related grade 3--4 adverse effects were mainly leukopenia (36%), dizziness (9%), and vomiting (3%). In our study, to ensure safety and avoid unnecessary drug reductions during FLOT administration, we used prophylactic antiemetics in each patient. Additionally, granulocyte-colony stimulating factor (G-CSF) was used for patients with fewer than 4 × 10^9^ leukocytes. Leukopenia and vomiting remained the most predominant side effects of chemotherapy with results similar to those observed in the FLOT4 trial, but these were clinically acceptable grade 3--4 toxicities.[@CIT0022] In the present study, no patient dropped out due to unbearable or severe side effects and no treatment-related deaths occurred.

Our study has some limitations and deficiencies. First, there were only 47 patients in the FLOT-first group, and the effect of FLOT for patients without lymph node metastasis still needs to be verified by a larger sample; second, as a retrospective study, although the statistical method based on the propensity score can effectively eliminate observed confounders, it cannot control for unobserved confounders; thus, it is impossible to reach the level of evidence of randomized controlled studies. However, the efficacy of the FLOT regimen for patients with LAGC within the tolerable toxicity levels is consistent with the results of previous studies. Furthermore, tumor staging and efficacy evaluation were all conducted through CT, gastroscopy, or MRI. Similar to many previous studies, these traditional methods can only evaluate tumors and tumor changes from a morphological point of view. It is difficult to achieve an accurate evaluation, and a high degree of consistency cannot be maintained with pathological findings, which may affect the matching and comparison of the two groups of patients.

Conclusion {#S0005}
==========

Our study demonstrated that preoperative FLOT regimen chemotherapy was superior to initial surgery for patients with LAGC in terms of OS. We suggest that the use of the FLOT regimen as neoadjuvant chemotherapy should be taken into consideration during the comprehensive treatment of patients with LAGC. Rigorous randomized studies are needed to determine the role of FLOT and optimal patient selection in the Chinese population.
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Table S1Univariate and multivariate analysis of survival before PSM analysis (n=313)VariablesUnivariate analysis*P-*valueMultivariate analysis*P-*valueHR95% CIHR95% CITreatment0.0160.004 FLOT-first0.5220.307\~0.8860.4170.23\~0.755 Surgery-first11Age0.802 \<601 ≥601.0390.768\~1.406Gender0.928 Male1 Female1.0160.726\~1.422Lauren classification0.0220.109 Intestinal11 Diffuse1.6191.147\~2.2861.4120.997\~1.999 Mixed1.1870.801!1.7591.0220.685\~1.524Tumor location0.426 Upper third1 Middle third1.0460.703\~1.557 Lower third1.2770.843\~1.933Clinical TNM stage\<0.001\<0.001 II11 III2.8782.047\~4.0443.1222.197\~4.438Diagnose time0.357 2013\~20141 2015\~20160.8480.615\~1.170 20170.6980.393\~1.240Postoperative chemotherapy0.0490.21 FLOT11 FOLFOX61.2350.83\~1.8380.9040.581\~1.405 XELOX1.6621.082\~2.5540.7510.48\~1.178 SOX1.6141.072\~2.4291.2350.766\~1.99Style of operation0.062 Total gastrectomy1 Subtotal gastrectomy1.2410.898\~1.715 Distal gastrectomy0.7140.437\~1.168[^6] Table S2Univariate and multivariate analysis of survival in patients received preoperative FLOT chemotherapy (n=45)VariablesUnivariate analysis*P-*valueMultivariate analysis*P-*valueHR95% CIHR95% CIAge (years)0.809 \<601 ≥601.1520.367\~3.619Gender0.020.01 Male11 Female3.831.236\~11,8666.3221.75--22.91Lauren classification0.167 Intestinal1 Diffuse2.7730.801\~9.601 Mixed0.8640.158\~4.729Tumor location0.866 Upper third1 Middle third1.2720.255\~6.348 Lower third1.5950.276\~9.212Clinical TNM stage0.516 II1 III1.5380.419\~5.643Diagnose time0.793 2013\~20141 2015\~20160.7670.195\~3.02 20171.2560.243\~6.502Style of operation0.412 Total gastrectomy1 Subtotal gastrectomy1.0790.346\~3.362 Distal gastrectomy0.440.109\~1.776Response0.0090.005 CR+PR11 SD+PD5.6551.251--25.588.211.66--40.56[^7]

[^1]: **Abbreviations:** PSM, propensity matched; FLOT, docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil.

[^2]: **Abbreviations:** FLOT, docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil; PSM, propensity score -- matched; IPTW, inverse probability of treatment weighting.

[^3]: **Notes:** Adjusted HR (95%) was adjusted by age, gender, Lauren classification, tumor location, clinical TNM stage, diagnose time, postoperative chemotherapy, and style of operation. Variables that had no significant differences in univariate analysis were not included in the multivariate analysis.

    **Abbreviations:** PSM, propensity matched; FLOT, docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil; FOLFOX6, oxaliplatin, leucovorin and 5-fluorouracil.

[^4]: **Abbreviations:** CR, complete response; PR, partial response; SD, stable disease; PD, progression of disease; NE, not evaluable.

[^5]: **Note:** ^a^Grade 3--5 Clavien‒Dindo classification.

    **Abbreviations:** FLOT, docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil; PSM, propensity matched; pT, pathological tumor invasion; pN, pathological lymph node metastasis; N, number.

[^6]: **Notes:** Adjusted HR (95%) was adjusted by age, gender, Lauren classification, tumor location, clinical TNM stage, diagnose time, postoperative chemotherapy, and style of operation. Variables that had no significant differences in univariate analysis were not included in the multivariate analysis. Three patients were excluded from the analysis because they died within 1 month after surgery and they did not receive postoperative chemotherapy.

    **Abbreviations:** PSM, propensity matched; FLOT, docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil; FOLFOX6, oxaliplatin, leucovorin, and 5-fluorouracil.

[^7]: **Notes:** Adjusted HR (95%) was adjusted by age, gender, Lauren classification, tumor location, clinical TNM stage, diagnose time, style of operation, and response. Variables that had no significant differences in univariate analysis were not included in the multivariate analysis. Two patients lost the data of response and were excluded from the analysis.

    **Abbreviations:** FLOT, docetaxel, oxaliplatin, leucovorin, and 5-Fluorouracilf; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
